asalyxabio

We are a company focused on the development of the ASX-100 neutrophil targeting platform to treat significant unmet medical needs

[asalyxabio @asalyxabio]

Listen to our founder Marc Appel speak with Mark Bayer about innovation and driving factors in the biotech industry, link is in our bio. https://t.co/2bOm9iE2De